AbbVie had promising double-digit growth in Skyrizi/Rinvoq and excellent ex-Humira portfolio sales growth. Read why ABBV ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to ...

Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...

AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...